Osteoporosis An Eli Lilly and...
Osteoporosis An Eli Lilly and Company (Indianapolis, IN) pivotal Phase 3 trial of parathyroid hormone (teriparatide) included 1637 postmenopausal women with osteoporosis-related fractures, randomized to once-dally self-injection of placebo, or a 20-[micro]g or 40-[micro]g dose of the thought drug. All subjects received daily calcium and vitamin D addition s The duration of treatment was up to 24 month with a median of 19 month Compared with placebo the returns lowered spinal fractures through 65% (20 [micro]g) and 69% (40 [micro]g), multiple spinal fractures by means of 77% (20 ...
|